Calorie restriction and resveratrol in cardiovascular health and disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 11, 2011, Pages 1477-1489

  Dolinsky, Vernon W ^a   Dyck, Jason R B ^a  

^a MAZANKOWSKI ALBERTA HEART INSTITUTE   (Canada)

Author keywords

AMP activated protein kinase; Calorie restriction; Cardiovascular disease; Nitric oxide; Resveratrol; Sirtuin

Indexed keywords

ADIPONECTIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN KINASE B; RESVERATROL; SILENT INFORMATION REGULATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CLINICAL EFFECTIVENESS; DIABETIC CARDIOMYOPATHY; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MITOCHONDRION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; MICROARRAY ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; THERAPY EFFECT; TRANSCRIPTION REGULATION; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM; VASODILATATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALORIC RESTRICTION; CARDIOVASCULAR DISEASES; HUMANS; STILBENES; VASODILATOR AGENTS;

ANIMALIA;

EID: 80053456372     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.06.010     Document Type: Review

References (187)

1. Roger V.L., Go A.S., Lloyd-Jones D.M., Adams R.J., Berry J.D., Brown T.M., Carnethon M.R., Dai S., de Simone G., Ford E.S., Fox C.S., Fullerton H.J., Gillespie C., Greenlund K.J., Hailpern S.M., Heit J.A., Ho P.M., Howard V.J., Kissela B.M., Kittner S.J., Lackland D.T., Lichtman J.H., Lisabeth L.D., Makuc D.M., Marcus G.M., Marelli A., Matchar D.B., McDermott M.M., Meigs J.B., Moy C.S., Mozaffarian D., Mussolino M.E., Nichol G., Paynter N.P., Rosamond W.D., Sorlie P.D., Stafford R.S., Turan T.N., Turner M.B., Wong N.D., Wylie-Rosett J. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-e209.
2. Ravussin E., Smith S.R. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann. N. Y. Acad. Sci. 2002, 967:363-378.
3. Bertoni A.G., Goff D.C., D'Agostino R.B., Liu K., Hundley W.G., Lima J.A., Polak J.F., Saad M.F., Szklo M., Tracy R.P., Siscovick D.S. Diabetic cardiomyopathy and subclinical cardiovascular disease: the Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care 2006, 29:588-594.
4. Das M., Gabriely I., Barzilai N. Caloric restriction, body fat and ageing in experimental models. Obes. Rev. 2004, 5:13-19.
5. Fontana L. Calorie restriction and cardiometabolic health. Eur. J. Cardiovasc. Prev. Rehabil. 2008, 15:3-9.
6. Colman R.J., Anderson R.M., Johnson S.C., Kastman E.K., Kosmatka K.J., Beasley T.M., Allison D.B., Cruzen C., Simmons H.A., Kemnitz J.W., Weindruch R. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science 2009, 325:201-204.
7. Sohal R.S., Ku H.H., Agarwal S., Forster M.J., Lal H. Oxidative damage, mitochondrial oxidant generation and antioxidant defenses during aging and in response to food restriction in the mouse. Mech. Ageing Dev. 1994, 74:121-133.
8. Judge S., Jang Y.M., Smith A., Hagen T., Leeuwenburgh C. Age-associated increases in oxidative stress and antioxidant enzyme activities in cardiac interfibrillar mitochondria: implications for the mitochondrial theory of aging. FASEB J. 2005, 19:419-421.
9. Hayakawa M., Hattori K., Sugiyama S., Ozawa T. Age-associated oxygen damage and mutations in mitochondrial DNA in human hearts. Biochem. Biophys. Res. Commun. 1992, 189:979-985.
10. Rodriguez-Manas L., El-Assar M., Vallejo S., Lopez-Doriga P., Solis J., Petidier R., Montes M., Nevado J., Castro M., Gomez-Guerrero C., Peiro C., Sanchez-Ferrer C.F. Endothelial dysfunction in aged humans is related with oxidative stress and vascular inflammation. Aging Cell 2009, 8:226-238.
11. Grieve D.J., Byrne J.A., Cave A.C., Shah A.M. Role of oxidative stress in cardiac remodelling after myocardial infarction. Heart Lung Circ. 2004, 13:132-138.
12. Seddon M., Looi Y.H., Shah A.M. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart 2007, 93:903-907.
13. Li J.M., Gall N.P., Grieve D.J., Chen M., Shah A.M. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 2002, 40:477-484.
14. Ide T., Tsutsui H., Kinugawa S., Utsumi H., Kang D., Hattori N., Uchida K., Arimura K., Egashira K., Takeshita A. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ. Res. 1999, 85:357-363.
15. Fontana L., Villareal D.T., Weiss E.P., Racette S.B., Steger-May K., Klein S., Holloszy J.O. Calorie restriction or exercise: effects on coronary heart disease risk factors. A randomized, controlled trial. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E197-E202.
16. Seymour E.M., Parikh R.V., Singer A.A., Bolling S.F. Moderate calorie restriction improves cardiac remodeling and diastolic dysfunction in the Dahl-SS rat. J. Mol. Cell. Cardiol. 2006, 41:661-668.
17. Rippe C., Lesniewski L., Connell M., LaRocca T., Donato A., Seals D. Short-term calorie restriction reverses vascular endothelial dysfunction in old mice by increasing nitric oxide and reducing oxidative stress. Aging Cell 2010, 9:304-312.
18. Colom B., Oliver J., Roca P., Garcia-Palmer F.J. Caloric restriction and gender modulate cardiac muscle mitochondrial H2O2 production and oxidative damage. Cardiovasc. Res. 2007, 74:456-465.
19. Gredilla R., Sanz A., Lopez-Torres M., Barja G. Caloric restriction decreases mitochondrial free radical generation at complex I and lowers oxidative damage to mitochondrial DNA in the rat heart. FASEB J. 2001, 15:1589-1591.
20. Pamplona R., Portero-Otin M., Requena J., Gredilla R., Barja G. Oxidative, glycoxidative and lipoxidative damage to rat heart mitochondrial proteins is lower after 4months of caloric restriction than in age-matched controls. Mech. Ageing Dev. 2002, 123:1437-1446.
21. Mattison J.A., Lane M.A., Roth G.S., Ingram D.K. Calorie restriction in rhesus monkeys. Exp. Gerontol. 2003, 38:35-46.
22. Park S., Komatsu T., Hayashi H., Yamaza H., Chiba T., Higami Y., Kuramoto K., Shimokawa I. Calorie restriction initiated at middle age improved glucose tolerance without affecting age-related impairments of insulin signaling in rat skeletal muscle. Exp. Gerontol. 2006, 41:837-845.
23. Csiszar A., Labinskyy N., Jimenez R., Pinto J.T., Ballabh P., Losonczy G., Pearson K.J., de Cabo R., Ungvari Z. Anti-oxidative and anti-inflammatory vasoprotective effects of caloric restriction in aging: role of circulating factors and SIRT1. Mech. Ageing Dev. 2009, 130:518-527.
24. Castello L., Froio T., Maina M., Cavallini G., Biasi F., Leonarduzzi G., Donati A., Bergamini E., Poli G., Chiarpotto E. Alternate-day fasting protects the rat heart against age-induced inflammation and fibrosis by inhibiting oxidative damage and NF-kB activation. Free Radic. Biol. Med. 2010, 48:47-54.
25. Lee C.K., Allison D.B., Brand J., Weindruch R., Prolla T.A. Transcriptional profiles associated with aging and middle age-onset caloric restriction in mouse hearts. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:14988-14993.
26. Wang F., Nguyen M., Qin F.X., Tong Q. SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction. Aging Cell 2007, 6:505-514.
27. Anderson R.M., Barger J.L., Edwards M.G., Braun K.H., O'Connor C.E., Prolla T.A., Weindruch R. Dynamic regulation of PGC-1alpha localization and turnover implicates mitochondrial adaptation in calorie restriction and the stress response. Aging Cell 2008, 7:101-111.
28. Corton J.C., Brown-Borg H.M. Peroxisome proliferator-activated receptor gamma coactivator 1 in caloric restriction and other models of longevity. J. Gerontol. A Biol. Sci. Med. Sci. 2005, 60:1494-1509.
29. Shinmura K., Tamaki K., Bolli R. Impact of 6-mo caloric restriction on myocardial ischemic tolerance: possible involvement of nitric oxide-dependent increase in nuclear Sirt1. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H2348-H2355.
30. Cohen H.Y., Miller C., Bitterman K.J., Wall N.R., Hekking B., Kessler B., Howitz K.T., Gorospe M., de Cabo R., Sinclair D.A. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004, 305:390-392.
31. Bordone L., Cohen D., Robinson A., Motta M.C., van Veen E., Czopik A., Steele A.D., Crowe H., Marmor S., Luo J., Gu W., Guarente L. SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell 2007, 6:759-767.
32. Edwards A.G., Donato A.J., Lesniewski L.A., Gioscia R.A., Seals D.R., Moore R.L. Life-long caloric restriction elicits pronounced protection of the aged myocardium: a role for AMPK. Mech. Ageing Dev. 2010, 131:739-742.
33. Dolinsky V.W., Morton J.S., Oka T., Robillard-Frayne I., Bagdan M., Lopaschuk G.D., Des Rosiers C., Walsh K., Davidge S.T., Dyck J.R. Calorie restriction prevents hypertension and cardiac hypertrophy in the spontaneously hypertensive rat. Hypertension 2010, 56:412-421.
34. Giani J.F., Bonkowski M.S., Munoz M.C., Masternak M.M., Turyn D., Bartke A., Dominici F.P. Insulin signaling cascade in the hearts of long-lived growth hormone receptor knockout mice: effects of calorie restriction. J. Gerontol. A Biol. Sci. Med. Sci. 2008, 63:788-797.
35. McCurdy C.E., Cartee G.D. Akt2 is essential for the full effect of calorie restriction on insulin-stimulated glucose uptake in skeletal muscle. Diabetes 2005, 54:1349-1356.
36. Chen D., Bruno J., Easlon E., Lin S.J., Cheng H.L., Alt F.W., Guarente L. Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev. 2008, 22:1753-1757.
37. Gonzalez A.A., Kumar R., Mulligan J.D., Davis A.J., Weindruch R., Saupe K.W. Metabolic adaptations to fasting and chronic caloric restriction in heart, muscle, and liver do not include changes in AMPK activity. Am. J. Physiol. Endocrinol. Metab. 2004, 287:E1032-E1037.
38. To K., Yamaza H., Komatsu T., Hayashida T., Hayashi H., Toyama H., Chiba T., Higami Y., Shimokawa I. Down-regulation of AMP-activated protein kinase by calorie restriction in rat liver. Exp. Gerontol. 2007, 42:1063-1071.
39. Kemi M., Keenan K.P., McCoy C., Hoe C.M., Soper K.A., Ballam G.C., van Zwieten M.J. The relative protective effects of moderate dietary restriction versus dietary modification on spontaneous cardiomyopathy in male Sprague-Dawley rats. Toxicol. Pathol. 2000, 28:285-296.
40. Lefevre M., Redman L.M., Heilbronn L.K., Smith J.V., Martin C.K., Rood J.C., Greenway F.L., Williamson D.A., Smith S.R., Ravussin E. Caloric restriction alone and with exercise improves CVD risk in healthy non-obese individuals. Atherosclerosis 2009, 203:206-213.
41. Mahoney L.B., Denny C.A., Seyfried T.N. Caloric restriction in C57BL/6J mice mimics therapeutic fasting in humans. Lipids Health Dis. 2006, 5:13.
42. Lane M.A., Ingram D.K., Roth G.S. Calorie restriction in nonhuman primates: effects on diabetes and cardiovascular disease risk. Toxicol. Sci. 1999, 52:41-48.
43. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 1999, 340:115-126.
44. Guo Z., Mitchell-Raymundo F., Yang H., Ikeno Y., Nelson J., Diaz V., Richardson A., Reddick R. Dietary restriction reduces atherosclerosis and oxidative stress in the aorta of apolipoprotein E-deficient mice. Mech. Ageing Dev. 2002, 123:1121-1131.
45. Nicklas B.J., Ambrosius W., Messier S.P., Miller G.D., Penninx B.W., Loeser R.F., Palla S., Bleecker E., Pahor M. Diet-induced weight loss, exercise, and chronic inflammation in older, obese adults: a randomized controlled clinical trial. Am. J. Clin. Nutr. 2004, 79:544-551.
46. Fontana L., Meyer T.E., Klein S., Holloszy J.O. Long-term calorie restriction is highly effective in reducing the risk for atherosclerosis in humans. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:6659-6663.
47. Young J.B., Mullen D., Landsberg L. Caloric restriction lowers blood pressure in the spontaneously hypertensive rat. Metabolism 1978, 27:1711-1714.
48. Overton J.M., VanNess J.M., Casto R.M. Food restriction reduces sympathetic support of blood pressure in spontaneously hypertensive rats. J. Nutr. 1997, 127:655-660.
49. Swoap S.J., Boddell P., Baldwin K.M. Interaction of hypertension and caloric restriction on cardiac mass and isomyosin expression. Am. J. Physiol. 1995, 268:R33-R39.
50. VanNess J.M., Casto R.M., Overton J.M. Antihypertensive effects of food-intake restriction in aortic coarctation hypertension. J. Hypertens. 1997, 15:1253-1262.
51. Mattagajasingh I., Kim C.S., Naqvi A., Yamamori T., Hoffman T.A., Jung S.B., DeRicco J., Kasuno K., Irani K. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14855-14860.
52. Zanetti M., Barazzoni R., Vadori M., Stebel M., Biolo G., Guarnieri G. Lack of direct effect of moderate hyperleptinemia to improve endothelial function in lean rat aorta: role of calorie restriction. Atherosclerosis 2004, 175:253-259.
53. Sasaki S., Higashi Y., Nakagawa K., Kimura M., Noma K., Hara K., Matsuura H., Goto C., Oshima T., Chayama K. A low-calorie diet improves endothelium-dependent vasodilation in obese patients with essential hypertension. Am. J. Hypertens. 2002, 15:302-309.
54. Meyer T.E., Kovacs S.J., Ehsani A.A., Klein S., Holloszy J.O., Fontana L. Long-term caloric restriction ameliorates the decline in diastolic function in humans. J. Am. Coll. Cardiol. 2006, 47:398-402.
55. Cicogna A.C., Padovani C.R., Okoshi K., Aragon F.F., Okoshi M.P. Myocardial function during chronic food restriction in isolated hypertrophied cardiac muscle. Am. J. Med. Sci. 2000, 320:244-248.
56. Taffet G.E., Pham T.T., Hartley C.J. The age-associated alterations in late diastolic function in mice are improved by caloric restriction. J. Gerontol. A Biol. Sci. Med. Sci. 1997, 52:B285-B290.
57. Abete P., Testa G., Ferrara N., De Santis D., Capaccio P., Viati L., Calabrese C., Cacciatore F., Longobardi G., Condorelli M., Napoli C., Rengo F. Cardioprotective effect of ischemic preconditioning is preserved in food-restricted senescent rats. Am. J. Physiol. Heart Circ. Physiol. 2002, 282:H1978-H1987.
58. Long P., Nguyen Q., Thurow C., Broderick T.L. Caloric restriction restores the cardioprotective effect of preconditioning in the rat heart. Mech. Ageing Dev. 2002, 123:1411-1413.
59. Broderick T.L., Belke T., Driedzic W.R. Effects of chronic caloric restriction on mitochondrial respiration in the ischemic reperfused rat heart. Mol. Cell. Biochem. 2002, 233:119-125.
60. Chandrasekar B., Nelson J.F., Colston J.T., Freeman G.L. Calorie restriction attenuates inflammatory responses to myocardial ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2001, 280:H2094-H2102.
61. Shinmura K., Tamaki K., Bolli R. Short-term caloric restriction improves ischemic tolerance independent of opening of ATP-sensitive K+channels in both young and aged hearts. J. Mol. Cell. Cardiol. 2005, 39:285-296.
62. Shinmura K., Tamaki K., Saito K., Nakano Y., Tobe T., Bolli R. Cardioprotective effects of short-term caloric restriction are mediated by adiponectin via activation of AMP-activated protein kinase. Circulation 2007, 116:2809-2817.
63. Sung M.M., Soltys C.L., Masson G., Boisvenue J.J., Dyck J.R. Improved cardiac metabolism and activation of the RISK pathway contributes to improved post-ischemic recovery in calorie restricted mice. J. Mol. Med. 2011, 89:291-302.
64. Kondo M., Shibata R., Miura R., Shimano M., Kondo K., Li P., Ohashi T., Kihara S., Maeda N., Walsh K., Ouchi N., Murohara T. Caloric restriction stimulates revascularization in response to ischemia via adiponectin-mediated activation of eNOS. J. Biol. Chem. 2009, 284:1718-1724.
65. Jaswal J.S., Keung W., Wang W., Ussher J.R., Lopaschuk G.D. Targeting fatty acid and carbohydrate oxidation - A novel therapeutic intervention in the ischemic and failing heart. Biochim. Biophys. Acta 2011, 1813:1333-1350.
66. Dhahbi J.M., Tsuchiya T., Kim H.J., Mote P.L., Spindler S.R. Gene expression and physiologic responses of the heart to the initiation and withdrawal of caloric restriction. J. Gerontol. A Biol. Sci. Med. Sci. 2006, 61:218-231.
67. Swindell W.R. Genes regulated by caloric restriction have unique roles within transcriptional networks. Mech. Ageing Dev. 2008, 129:580-592.
68. Signorelli P., Ghidoni R. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J. Nutr. Biochem. 2005, 16:449-466.
69. Huang W.Y., Cai Y.Z., Xing J., Corke H., Sun M. Comparative analysis of bioactivities of four Polygonum species. Planta Med. 2008, 74:43-49.
70. Brisdelli F., D'Andrea G., Bozzi A. Resveratrol: a natural polyphenol with multiple chemopreventive properties. Curr. Drug Metab. 2009, 10:530-546.
71. Mikulski D., Gorniak R., Molski M. A theoretical study of the structure-radical scavenging activity of trans-resveratrol analogues and cis-resveratrol in gas phase and water environment. Eur. J. Med. Chem. 2010, 45:1015-1027.
72. Boocock D.J., Patel K.R., Faust G.E., Normolle D.P., Marczylo T.H., Crowell J.A., Brenner D.E., Booth T.D., Gescher A., Steward W.P. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 848:182-187.
73. Vitaglione P., Sforza S., Galaverna G., Ghidini C., Caporaso N., Vescovi P.P., Fogliano V., Marchelli R. Bioavailability of trans-resveratrol from red wine in humans. Mol. Nutr. Food Res. 2005, 49:495-504.
74. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., Pistell P.J., Poosala S., Becker K.G., Boss O., Gwinn D., Wang M., Ramaswamy S., Fishbein K.W., Spencer R.G., Lakatta E.G., Le Couteur D., Shaw R.J., Navas P., Puigserver P., Ingram D.K., de Cabo R., Sinclair D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
75. Hao H.D., He L.R. Mechanisms of cardiovascular protection by resveratrol. J. Med. Food 2004, 7:290-298.
76. Sun C., Zhang F., Ge X., Yan T., Chen X., Shi X., Zhai Q. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab. 2007, 6:307-319.
77. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
78. Um J.H., Park S.J., Kang H., Yang S., Foretz M., McBurney M.W., Kim M.K., Viollet B., Chung J.H. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010, 59:554-563.
79. Brasnyo P., Molnar G.A., Mohas M., Marko L., Laczy B., Cseh J., Mikolas E., Szijarto I.A., Merei A., Halmai R., Meszaros L.G., Sumegi B., Wittmann I. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 2011, 1-7.
80. Antosh M., Whitaker R., Kroll A., Hosier S., Chang C., Bauer J., Cooper L., Neretti N., Helfand S.L. Comparative transcriptional pathway bioinformatic analysis of dietary restriction, Sir2, p53 and resveratrol life span extension in Drosophila. Cell Cycle 2011, 10:904-911.
81. Barger J.L., Kayo T., Vann J.M., Arias E.B., Wang J., Hacker T.A., Wang Y., Raederstorff D., Morrow J.D., Leeuwenburgh C., Allison D.B., Saupe K.W., Cartee G.D., Weindruch R., Prolla T.A. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 2008, 3:e2264.
82. Barger J.L., Kayo T., Pugh T.D., Prolla T.A., Weindruch R. Short-term consumption of a resveratrol-containing nutraceutical mixture mimics gene expression of long-term caloric restriction in mouse heart. Exp. Gerontol. 2008, 43:859-866.
83. Pearson K.J., Baur J.A., Lewis K.N., Peshkin L., Price N.L., Labinskyy N., Swindell W.R., Kamara D., Minor R.K., Perez E., Jamieson H.A., Zhang Y., Dunn S.R., Sharma K., Pleshko N., Woollett L.A., Csiszar A., Ikeno Y., Le Couteur D., Elliott P.J., Becker K.G., Navas P., Ingram D.K., Wolf N.S., Ungvari Z., Sinclair D.A., de Cabo R. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008, 8:157-168.
84. Lekakis J., Rallidis L.S., Andreadou I., Vamvakou G., Kazantzoglou G., Magiatis P., Skaltsounis A.L., Kremastinos D.T. Polyphenolic compounds from red grapes acutely improve endothelial function in patients with coronary heart disease. Eur. J. Cardiovasc. Prev. Rehabil. 2005, 12:596-600.
85. Hashimoto M., Kim S., Eto M., Iijima K., Ako J., Yoshizumi M., Akishita M., Kondo K., Itakura H., Hosoda K., Toba K., Ouchi Y. Effect of acute intake of red wine on flow-mediated vasodilatation of the brachial artery. Am. J. Cardiol. 2001, 88:1457-1460. (A1459).
86. Goh S.S., Woodman O.L., Pepe S., Cao A.H., Qin C., Ritchie R.H. The red wine antioxidant resveratrol prevents cardiomyocyte injury following ischemia-reperfusion via multiple sites and mechanisms. Antioxid. Redox. Signal. 2007, 9:101-113.
87. Xu Q., Hao X., Yang Q., Si L. Resveratrol prevents hyperglycemia-induced endothelial dysfunction via activation of adenosine monophosphate-activated protein kinase. Biochem. Biophys. Res. Commun. 2009, 388:389-394.
88. Soylemez S., Sepici A., Akar F. Resveratrol supplementation gender independently improves endothelial reactivity and suppresses superoxide production in healthy rats. Cardiovasc. Drugs Ther. 2009, 23:449-458.
89. Rush J.W., Quadrilatero J., Levy A.S., Ford R.J. Chronic resveratrol enhances endothelium-dependent relaxation but does not alter eNOS levels in aorta of spontaneously hypertensive rats. Exp. Biol. Med. (Maywood) 2007, 232:814-822.
90. Toklu H.Z., Sehirli O., Ersahin M., Suleymanoglu S., Yiginer O., Emekli-Alturfan E., Yarat A., Yegen B.C., Sener G. Resveratrol improves cardiovascular function and reduces oxidative organ damage in the renal, cardiovascular and cerebral tissues of two-kidney, one-clip hypertensive rats. J. Pharm. Pharmacol. 2010, 62:1784-1793.
91. Nicholson S.K., Tucker G.A., Brameld J.M. Effects of dietary polyphenols on gene expression in human vascular endothelial cells. Proc. Nutr. Soc. 2008, 67:42-47.
92. Wallerath T., Deckert G., Ternes T., Anderson H., Li H., Witte K., Forstermann U. Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 2002, 106:1652-1658.
93. Miatello R., Vazquez M., Renna N., Cruzado M., Zumino A.P., Risler N. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am. J. Hypertens. 2005, 18:864-870.
94. Leikert J.F., Rathel T.R., Wohlfart P., Cheynier V., Vollmar A.M., Dirsch V.M. Red wine polyphenols enhance endothelial nitric oxide synthase expression and subsequent nitric oxide release from endothelial cells. Circulation 2002, 106:1614-1617.
95. Zou J.G., Wang Z.R., Huang Y.Z., Cao K.J., Wu J.M. Effect of red wine and wine polyphenol resveratrol on endothelial function in hypercholesterolemic rabbits. Int. J. Mol. Med. 2003, 11:317-320.
96. Lekli I., Szabo G., Juhasz B., Das S., Das M., Varga E., Szendrei L., Gesztelyi R., Varadi J., Bak I., Das D.K., Tosaki A. Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H859-H866.
97. Liu Z., Song Y., Zhang X., Liu Z., Zhang W., Mao W., Wang W., Cui W., Zhang X., Jia X., Li N., Han C., Liu C. Effects of trans-resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model. Clin. Exp. Pharmacol. Physiol. 2005, 32:1049-1054.
98. Miyazaki R., Ichiki T., Hashimoto T., Inanaga K., Imayama I., Sadoshima J., Sunagawa K. SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1263-1269.
99. Haider U.G., Sorescu D., Griendling K.K., Vollmar A.M., Dirsch V.M. Resveratrol suppresses angiotensin II-induced Akt/protein kinase B and p70 S6 kinase phosphorylation and subsequent hypertrophy in rat aortic smooth muscle cells. Mol. Pharmacol. 2002, 62:772-777.
100. Arunachalam G., Yao H., Sundar I.K., Caito S., Rahman I. SIRT1 regulates oxidant- and cigarette smoke-induced eNOS acetylation in endothelial cells: role of resveratrol. Biochem. Biophys. Res. Commun. 2010, 393:66-72.
101. Csiszar A., Labinskyy N., Pinto J.T., Ballabh P., Zhang H., Losonczy G., Pearson K., de Cabo R., Pacher P., Zhang C., Ungvari Z. Resveratrol induces mitochondrial biogenesis in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H13-H20.
102. Chen Z.P., Mitchelhill K.I., Michell B.J., Stapleton D., Rodriguez-Crespo I., Witters L.A., Power D.A., Ortiz de Montellano P.R., Kemp B.E. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett. 1999, 443:285-289.
103. Robich M.P., Osipov R.M., Nezafat R., Feng J., Clements R.T., Bianchi C., Boodhwani M., Coady M.A., Laham R.J., Sellke F.W. Resveratrol improves myocardial perfusion in a swine model of hypercholesterolemia and chronic myocardial ischemia. Circulation 2011, 122:S142-S149.
104. O'Leary K.A., de Pascual-Tereasa S., Needs P.W., Bao Y.P., O'Brien N.M., Williamson G. Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription. Mutat. Res. 2004, 551:245-254.
105. Wang M.J., Huang H.M., Hsieh S.J., Jeng K.C., Kuo J.S. Resveratrol inhibits interleukin-6 production in cortical mixed glial cells under hypoxia/hypoglycemia followed by reoxygenation. J. Neuroimmunol. 2001, 112:28-34.
106. Culpitt S.V., Rogers D.F., Fenwick P.S., Shah P., De Matos C., Russell R.E., Barnes P.J., Donnelly L.E. Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 2003, 58:942-946.
107. Zhong M., Cheng G.F., Wang W.J., Guo Y., Zhu X.Y., Zhang J.T. Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. Phytomedicine 1999, 6:79-84.
108. Inanaga K., Ichiki T., Matsuura H., Miyazaki R., Hashimoto T., Takeda K., Sunagawa K. Resveratrol attenuates angiotensin II-induced interleukin-6 expression and perivascular fibrosis. Hypertens. Res. 2009, 32:466-471.
109. Rius C., Abu-Taha M., Hermenegildo C., Piqueras L., Cerda-Nicolas J.M., Issekutz A.C., Estan L., Cortijo J., Morcillo E.J., Orallo F., Sanz M.J. Trans- but not cis-resveratrol impairs angiotensin-II-mediated vascular inflammation through inhibition of NF-kappaB activation and peroxisome proliferator-activated receptor-gamma upregulation. J. Immunol. 2010, 185:3718-3727.
110. Rivera L., Moron R., Zarzuelo A., Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem. Pharmacol. 2009, 77:1053-1063.
111. Wang A., Liu M., Liu X., Dong L.Q., Glickman R.D., Slaga T.J., Zhou Z., Liu F. Up-regulation of adiponectin by resveratrol: the essential roles of the Akt/FOXO1 and AMP-activated protein kinase signaling pathways and DsbA-L. J. Biol. Chem. 2011, 286:60-66.
112. Ungvari Z., Orosz Z., Rivera A., Labinskyy N., Xiangmin Z., Olson S., Podlutsky A., Csiszar A. Resveratrol increases vascular oxidative stress resistance. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H2417-H2424.
113. Spanier G., Xu H., Xia N., Tobias S., Deng S., Wojnowski L., Forstermann U., Li H. Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4). J. Physiol. Pharmacol. 2009, 60(Suppl 4):111-116.
114. Kao C.L., Chen L.K., Chang Y.L., Yung M.C., Hsu C.C., Chen Y.C., Lo W.L., Chen S.J., Ku H.H., Hwang S.J. Resveratrol protects human endothelium from H(2)O(2)-induced oxidative stress and senescence via SirT1 activation. J. Atheroscler. Thromb. 2010, 17:970-979.
115. Ungvari Z., Labinskyy N., Mukhopadhyay P., Pinto J.T., Bagi Z., Ballabh P., Zhang C., Pacher P., Csiszar A. Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2009, 297:H1876-H1881.
116. Frankel E.N., Waterhouse A.L., Kinsella J.E. Inhibition of human LDL oxidation by resveratrol. Lancet 1993, 341:1103-1104.
117. Belguendouz L., Fremont L., Linard A. Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem. Pharmacol. 1997, 53:1347-1355.
118. Fremont L., Belguendouz L., Delpal S. Antioxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids. Life Sci. 1999, 64:2511-2521.
119. Auger C., Teissedre P.L., Gerain P., Lequeux N., Bornet A., Serisier S., Besancon P., Caporiccio B., Cristol J.P., Rouanet J.M. Dietary wine phenolics catechin, quercetin, and resveratrol efficiently protect hypercholesterolemic hamsters against aortic fatty streak accumulation. J. Agric. Food Chem. 2005, 53:2015-2021.
120. Berrougui H., Grenier G., Loued S., Drouin G., Khalil A. A new insight into resveratrol as an atheroprotective compound: inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis 2009, 207:420-427.
121. Kitada M., Kume S., Imaizumi N., Koya D. Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes 2011, 60:634-643.
122. Robich M.P., Chu L.M., Chaudray M., Nezafat R., Han Y., Clements R.T., Laham R.J., Manning W.J., Coady M.A., Sellke F.W. Anti-angiogenic effect of high-dose resveratrol in a swine model of metabolic syndrome. Surgery 2010, 148:453-462.
123. Olas B., Wachowicz B., Saluk-Juszczak J., Zielinski T. Effect of resveratrol, a natural polyphenolic compound, on platelet activation induced by endotoxin or thrombin. Thromb. Res. 2002, 107:141-145.
124. Wang Z., Huang Y., Zou J., Cao K., Xu Y., Wu J.M. Effects of red wine and wine polyphenol resveratrol on platelet aggregation in vivo and in vitro. Int. J. Mol. Med. 2002, 9:77-79.
125. Chan V., Fenning A., Iyer A., Hoey A., Brown L. Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats. Curr. Pharm. Biotechnol. 2011, 12:429-436.
126. Csiszar A., Labinskyy N., Olson S., Pinto J.T., Gupte S., Wu J.M., Hu F., Ballabh P., Podlutsky A., Losonczy G., de Cabo R., Mathew R., Wolin M.S., Ungvari Z. Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension 2009, 54:668-675.
127. Thandapilly S.J., Wojciechowski P., Behbahani J., Louis X.L., Yu L., Juric D., Kopilas M.A., Anderson H.D., Netticadan T. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am. J. Hypertens. 2010, 23:192-196.
128. Dolinsky V.W., Chan A.Y., Robillard Frayne I., Light P.E., Des Rosiers C., Dyck J.R. Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 2009, 119:1643-1652.
129. Mizutani K., Ikeda K., Kawai Y., Yamori Y. Protective effect of resveratrol on oxidative damage in male and female stroke-prone spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 2001, 28:55-59.
130. Behbahani J., Thandapilly S.J., Louis X.L., Huang Y., Shao Z., Kopilas M.A., Wojciechowski P., Netticadan T., Anderson H.D. Resveratrol and small artery compliance and remodeling in the spontaneously hypertensive rat. Am. J. Hypertens. 2010, 23:1273-1278.
131. Juric D., Wojciechowski P., Das D.K., Netticadan T. Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H2138-H2143.
132. Wojciechowski P., Juric D., Louis X.L., Thandapilly S.J., Yu L., Taylor C., Netticadan T. Resveratrol arrests and regresses the development of pressure overload- but not volume overload-induced cardiac hypertrophy in rats. J. Nutr. 2010, 140:962-968.
133. Hannan R.D., Jenkins A., Jenkins A.K., Brandenburger Y. Cardiac hypertrophy: a matter of translation. Clin. Exp. Pharmacol. Physiol. 2003, 30:517-527.
134. Chan A.Y., Dolinsky V.W., Soltys C.L., Viollet B., Baksh S., Light P.E., Dyck J.R. Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J. Biol. Chem. 2008, 283:24194-24201.
135. Sundaresan N.R., Pillai V.B., Samant S., Isbatan A., Gupta M., Gupta M.P. SIRT1-mediated deacetylation promotes Akt membrane localization and activation during development of cardiac hypertrophy. Abstract 19950: Meeting of the American Heart Association 2011.
136. Zarrinpashneh E., Beauloye C., Ginion A., Pouleur A.C., Havaux X., Hue L., Viollet B., Vanoverschelde J.L., Bertrand L. AMPKalpha2 counteracts the development of cardiac hypertrophy induced by isoproterenol. Biochem. Biophys. Res. Commun. 2008, 376:677-681.
137. Zhang P., Hu X., Xu X., Fassett J., Zhu G., Viollet B., Xu W., Wiczer B., Bernlohr D.A., Bache R.J., Chen Y. AMP activated protein kinase-alpha2 deficiency exacerbates pressure-overload-induced left ventricular hypertrophy and dysfunction in mice. Hypertension 2008, 52:918-924.
138. Sundaresan N.R., Pillai V.B., Gupta M.P. Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy. J. Mol. Cell. Cardiol. 2011, 51:614-618.
139. Alcendor R.R., Gao S., Zhai P., Zablocki D., Holle E., Yu X., Tian B., Wagner T., Vatner S.F., Sadoshima J. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ. Res. 2007, 100:1512-1521.
140. Li L., Zhao L., Yi-Ming W., Yu Y.S., Xia C.Y., Duan J.L., Su D.F. Sirt1 hyperexpression in SHR heart related to left ventricular hypertrophy. Can. J. Physiol. Pharmacol. 2009, 87:56-62.
141. Vahtola E., Louhelainen M., Merasto S., Martonen E., Penttinen S., Aahos I., Kyto V., Virtanen I., Mervaala E. Forkhead class O transcription factor 3a activation and Sirtuin1 overexpression in the hypertrophied myocardium of the diabetic Goto-Kakizaki rat. J. Hypertens. 2008, 26:334-344.
142. Pillai V.B., Sundaresan N.R., Kim G., Gupta M., Rajamohan S.B., Pillai J.B., Samant S., Ravindra P.V., Isbatan A., Gupta M.P. Exogenous NAD blocks cardiac hypertrophic response via activation of the SIRT3-LKB1-AMPK pathway. J. Biol. Chem. 2010, 285:3133-3144.
143. Wilkins B.J., Molkentin J.D. Calcium-calcineurin signaling in the regulation of cardiac hypertrophy. Biochem. Biophys. Res. Commun. 2004, 322:1178-1191.
144. Hattori R., Otani H., Maulik N., Das D.K. Pharmacological preconditioning with resveratrol: role of nitric oxide. Am. J. Physiol. Heart Circ. Physiol. 2002, 282:H1988-H1995.
145. Ray P.S., Maulik G., Cordis G.A., Bertelli A.A., Bertelli A., Das D.K. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic. Biol. Med. 1999, 27:160-169.
146. Shen M., Jia G.L., Wang Y.M., Ma H. Cardioprotective effect of resvaratrol pretreatment on myocardial ischemia-reperfusion induced injury in rats. Vascul. Pharmacol. 2006, 45:122-126.
147. Hung L.M., Su M.J., Chen J.K. Resveratrol protects myocardial ischemia-reperfusion injury through both NO-dependent and NO-independent mechanisms. Free Radic. Biol. Med. 2004, 36:774-781.
148. Xi J., Wang H., Mueller R.A., Norfleet E.A., Xu Z. Mechanism for resveratrol-induced cardioprotection against reperfusion injury involves glycogen synthase kinase 3beta and mitochondrial permeability transition pore. Eur. J. Pharmacol. 2009, 604:111-116.
149. Hwang J.T., Kwon D.Y., Park O.J., Kim M.S. Resveratrol protects ROS-induced cell death by activating AMPK in H9c2 cardiac muscle cells. Genes Nutr. 2008, 2:323-326.
150. Bradamante S., Barenghi L., Piccinini F., Bertelli A.A., De Jonge R., Beemster P., De Jong J.W. Resveratrol provides late-phase cardioprotection by means of a nitric oxide- and adenosine-mediated mechanism. Eur. J. Pharmacol. 2003, 465:115-123.
151. Kaga S., Zhan L., Matsumoto M., Maulik N. Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J. Mol. Cell. Cardiol. 2005, 39:813-822.
152. Penumathsa S.V., Koneru S., Samuel S.M., Maulik G., Bagchi D., Yet S.F., Menon V.P., Maulik N. Strategic targets to induce neovascularization by resveratrol in hypercholesterolemic rat myocardium: role of caveolin-1, endothelial nitric oxide synthase, hemeoxygenase-1, and vascular endothelial growth factor. Free Radic. Biol. Med. 2008, 45:1027-1034.
153. Chen Y.R., Yi F.F., Li X.Y., Wang C.Y., Chen L., Yang X.C., Su P.X., Cai J. Resveratrol attenuates ventricular arrhythmias and improves the long-term survival in rats with myocardial infarction. Cardiovasc. Drugs Ther. 2008, 22:479-485.
154. Fukuda S., Kaga S., Zhan L., Bagchi D., Das D.K., Bertelli A., Maulik N. Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1. Cell Biochem. Biophys. 2006, 44:43-49.
155. Chen P.L., Easton A.S. Anti-angiogenic effects of resveratrol on cerebral angiogenesis. Curr. Neurovasc. Res. 2011, 8:14-24.
156. Ganapathy S., Chen Q., Singh K.P., Shankar S., Srivastava R.K. Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. PLoS One 2010, 5:e15627.
157. Tseng S.H., Lin S.M., Chen J.C., Su Y.H., Huang H.Y., Chen C.K., Lin P.Y., Chen Y. Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin. Cancer Res. 2004, 10:2190-2202.
158. McMurray J.J., Pfeffer M.A. Heart failure. Lancet 2005, 365:1877-1889.
159. Tanno M., Kuno A., Yano T., Miura T., Hisahara S., Ishikawa S., Shimamoto K., Horio Y. Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J. Biol. Chem. 2010, 285:8375-8382.
160. Pinder M.C., Duan Z., Goodwin J.S., Hortobagyi G.N., Giordano S.H. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J. Clin. Oncol. 2007, 25:3808-3815.
161. Danz E.D., Skramsted J., Henry N., Bennett J.A., Keller R.S. Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic. Biol. Med. 2009, 46:1589-1597.
162. Tatlidede E., Sehirli O., Velioglu-Ogunc A., Cetinel S., Yegen B.C., Yarat A., Suleymanoglu S., Sener G. Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free. Radic. Res. 2009, 43:195-205.
163. Penumathsa S.V., Thirunavukkarasu M., Zhan L., Maulik G., Menon V.P., Bagchi D., Maulik N. Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J. Cell. Mol. Med. 2008, 12:2350-2361.
164. Silan C. The effects of chronic resveratrol treatment on vascular responsiveness of streptozotocin-induced diabetic rats. Biol. Pharm. Bull. 2008, 31:897-902.
165. Su H.C., Hung L.M., Chen J.K. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab. 2006, 290:E1339-E1346.
166. Thirunavukkarasu M., Penumathsa S.V., Koneru S., Juhasz B., Zhan L., Otani H., Bagchi D., Das D.K., Maulik N. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic. Biol. Med. 2007, 43:720-729.
167. Jing Y.H., Chen K.H., Yang S.H., Kuo P.C., Chen J.K. Resveratrol ameliorates vasculopathy in STZ-induced diabetic rats: role of AGE-RAGE signalling. Diabetes Metab. Res. Rev. 2010, 26:212-222.
168. Ungvari Z., Bagi Z., Feher A., Recchia F.A., Sonntag W.E., Pearson K., de Cabo R., Csiszar A. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am. J. Physiol. Heart Circ. Physiol. 2010, 299:H18-H24.
169. Paulson D.J. The diabetic heart is more sensitive to ischemic injury. Cardiovasc. Res. 1997, 34:104-112.
170. Chi T.C., Chen W.P., Chi T.L., Kuo T.F., Lee S.S., Cheng J.T., Su M.J. Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocin-induced diabetic rats. Life Sci. 2007, 80:1713-1720.
171. Katakam P.V., Jordan J.E., Snipes J.A., Tulbert C.D., Miller A.W., Busija D.W. Myocardial preconditioning against ischemia-reperfusion injury is abolished in Zucker obese rats with insulin resistance. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2007, 292:R920-R926.
172. Huang J.P., Huang S.S., Deng J.Y., Chang C.C., Day Y.J., Hung L.M. Insulin and resveratrol act synergistically, preventing cardiac dysfunction in diabetes, but the advantage of resveratrol in diabetics with acute heart attack is antagonized by insulin. Free Radic. Biol. Med. 2011, 49:1710-1721.
173. Sulaiman M., Matta M.J., Sunderesan N.R., Gupta M.P., Periasamy M., Gupta M. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 2010, 298:H833-H843.
174. Tao R., Coleman M.C., Pennington J.D., Ozden O., Park S.H., Jiang H., Kim H.S., Flynn C.R., Hill S., Hayes McDonald W., Olivier A.K., Spitz D.R., Gius D. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Mol. Cell 2010, 40:893-904.
175. Lan F., Cacicedo J.M., Ruderman N., Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J. Biol. Chem. 2008, 283:27628-27635.
176. Pacholec M., Bleasdale J.E., Chrunyk B., Cunningham D., Flynn D., Garofalo R.S., Griffith D., Griffor M., Loulakis P., Pabst B., Qiu X., Stockman B., Thanabal V., Varghese A., Ward J., Withka J., Ahn K. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 2010, 285:8340-8351.
177. Borra M.T., Smith B.C., Denu J.M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 2005, 280:17187-17195.
178. Dolinsky V.W., Dyck J.R. Role of AMP-activated protein kinase in healthy and diseased hearts. Am. J. Physiol. Heart Circ. Physiol. 2006, 291:H2557-H2569.
179. Yu J., Auwerx J. The role of SIRTs in the control of metabolic homeostasis. Ann. N. Y. Acad. Sci. 2009, 1173(Suppl 1):E10-E19.
180. Hou X., Xu S., Maitland-Toolan K.A., Sato K., Jiang B., Ido Y., Lan F., Walsh K., Wierzbicki M., Verbeuren T.J., Cohen R.A., Zang M. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J. Biol. Chem. 2008, 283:20015-20026.
181. Kovacic S., Soltys C.L., Barr A.J., Shiojima I., Walsh K., Dyck J.R. Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. J. Biol. Chem. 2003, 278:39422-39427.
182. Horman S., Vertommen D., Heath R., Neumann D., Mouton V., Woods A., Schlattner U., Wallimann T., Carling D., Hue L., Rider M.H. Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491. J. Biol. Chem. 2006, 281:5335-5340.
183. Soltys C.L., Kovacic S., Dyck J.R. Activation of cardiac AMP-activated protein kinase by LKB1 expression or chemical hypoxia is blunted by increased Akt activity. Am. J. Physiol. Heart Circ. Physiol. 2006, 290:H2472-H2479.
184. Chan A.Y., Soltys C.L., Young M.E., Proud C.G., Dyck J.R. Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J. Biol. Chem. 2004, 279:32771-32779.
185. Fulton D., Gratton J.P., McCabe T.J., Fontana J., Fujio Y., Walsh K., Franke T.F., Papapetropoulos A., Sessa W.C. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999, 399:597-601.
186. Park S., Komatsu T., Hayashi H., Trindade L.S., Yamaza H., Chiba T., Shimokawa I. Divergent regulation of adipose tissue metabolism by calorie restriction and inhibition of growth hormone signaling. Exp. Gerontol. 2009, 44:646-652.
187. Sharma N., Arias E.B., Bhat A.D., Sequea D.A., Ho S., Croff K.K., Sajan M.P., Farese R.V., Cartee G.D. Mechanisms for increased insulin-stimulated Akt phosphorylation and glucose uptake in fast- and slow-twitch skeletal muscles of calorie-restricted rats. Am. J. Physiol. Endocrinol. Metab. 2011, 300:E966-E978.